The HHS secretary has four new senior advisors to help him “move faster and go further” on his Make America Healthy Again agenda. The appointments preempt the GOP’s midterm messaging push.
HHS elevates officials into Kennedy’s inner circle in advance of midterms Read More »
An expanded collaboration between the two organizations will focus on prostate cancer and metastatic liver tumors, in addition to neurodegenerative disease.
Siemens Healthineers, Mayo Clinic partner on neurodegenerative disease, cancer Read More »
Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.
Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp Read More »
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation Read More »
New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
Dexcom seeks expanded Medicare coverage of CGMs for Type 2 diabetes Read More »
The Health Technology Ecosystem, which the HHS and CMS launched last summer, could accelerate advancements in data exchange and isn’t in competition with the ASTP’s own interoperability project, officials said.
TEFCA, Health Tech Ecosystem are complementary data sharing efforts: officials Read More »
The HHS secretary has four new senior advisors to help him “move faster and go further” on his Make America Healthy Again agenda. The appointments come in advance of the GOP’s midterm messaging push.
HHS elevates officials into Kennedy’s inner circle in advance of midterms Read More »
Analysts are keeping a close eye on Vertex’s kidney disease portfolio, anchored by the IgAN drug povetacicept, as its nonopioid painkiller Journavx is poised for “incremental” growth in the first half 2026, according to BMO Capital Markets.
Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.
¿Sabías que un interruptor magnetotérmico puede detectar una sobrecarga en tu red eléctrica más rápido que un parpadeo? ¿O que un analizador de redes trifásico vigila tu consumo como un halcón, midiendo voltajes y corrientes para evitar …
Grupo Novelec: tu tienda de materiales eléctricos en España Read More »
